Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
| Autor: | Pier Luigi Antignani, Giacomo Failla, Giorgio Ardita, Enrico Arosio, Luca Costanzo, Francesco Paolo Palumbo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.drug_class
Pneumonia Viral Low molecular weight heparin 030204 cardiovascular system & hematology Article coagulopathy Betacoronavirus 03 medical and health sciences 0302 clinical medicine D-dimer medicine Coagulopathy Humans pneumonia 030212 general & internal medicine Pandemics Coagulation Disorder SARS-CoV-2 business.industry low molecular weight heparin Anticoagulant Anticoagulants COVID-19 Thrombosis Heparin Blood Coagulation Disorders Heparin Low-Molecular-Weight medicine.disease Immunology Surgery Coronavirus Infections Cardiology and Cardiovascular Medicine Cytokine storm business medicine.drug |
| Zdroj: | Journal of Vascular Surgery: Venous and Lymphatic Disorders Journal of Vascular Surgery. Venous and Lymphatic Disorders |
| ISSN: | 2213-333X |
| DOI: | 10.1016/j.jvsv.2020.05.018 |
| Popis: | The SARS-CoV-2 (COVID-19) is causing a pandemic and potentially fatal disease of global public health concern. Viral infections are known to be associated with coagulation impairment; thus, thrombosis, hemorrhage, or both may occur. Understanding the pathophysiologic mechanisms underlying the development of coagulation disorders during viral infection is essential for the development of therapeutic strategies. Coagulopathy in COVID-19 infection is emerging as a precipitant factor for severe respiratory complications and death. An increase in coagulation markers, such as fibrinogen and D-dimer, has been found in severe COVID-19 cases. Heparin, clinically used as an anticoagulant, also has anti-inflammatory properties, including binding of inflammatory cytokines, inhibition of neutrophil chemotaxis, and protection of endothelial cells, and a potential antiviral effect. We hypothesized that low-molecular-weight heparin may attenuate cytokine storm in COVID-19 patients; therefore, low-molecular-weight heparin could be a valid adjunctive therapeutic drug for the treatment of COVID-19 pneumopathy. In this paper, we review potential mechanisms involved in coagulation impairment after viral infection and the possible role of heparin in the treatment of COVID-19 patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect